Table 1.
Patient Demographics.
| Characteristic | No. of patients (%) |
|---|---|
| N | 73 |
| Age, Years | |
| Median | 60 |
| Range | 33-86 |
| Gender | |
| Male | 40 (54.8) |
| Female | 33 (45.2) |
| ECOG Performance Status | |
| 0 | 37 (50.7) |
| 1 | 31 (42.5) |
| 2 | 5 (6.9) |
| Primary Cancer | |
| Non-small cell lung | 16 (22) |
| Breast | 16 (21.9) |
| Melanoma | 10 (13.7) |
| Head & neck | 9 (12.3) |
| Bladder | 6 (8.2) |
| Cholangiocarcinoma | 2 (2.7) |
| Esophageal | 2 (2.7) |
| Adenoid cystic of lung | 1 (1.4) |
| Adrenocortical carcinoma | 1 (1.4) |
| Ampulla of Vater | 1 (1.4) |
| Cervix | 1 (1.4) |
| Myxoid chondrosarcoma | 1 (1.4) |
| Prostate | 1 (1.4) |
| Small cell lung | 1 (1.4) |
| Stomach | 1 (1.4) |
| Uterine | 1 (1.4) |
| Olfactory esthesioneuroblastoma | 1 (1.9) |
| Carcinoma of unknown origin | 3 (4.1) |
| No. of prior therapy regimens (cytotoxic only) | |
| 0 | 33 (45.2) |
| 1 | 22 (30.1) |
| 2 | 12 (16.4) |
| 3 | 6 (8.2) |
| No. of cycles* | |
| Median | 4 |
| Range | 1-16 |
Abbreviation: ECOG PS: Eastern Cooperative Oncology Group performance status.
*
only cycles where veliparib was given were counted.